10-Q: ProKidney Reports Q3 2025 Results, Advances Kidney Therapy

ProKidney Corp. announced its third-quarter 2025 financial results, highlighting positive Phase 2 trial data for rilparencel and FDA alignment on its Phase 3 accelerated approval pathway, despite continued net losses and a need for future funding.

Summary

• Reported a net loss available to Class A common stockholders of $(16,469,000) for the three months ended September 30, 2025, an improvement from $(17,910,000) in the prior year period.
• Year-to-date net loss available to Class A common stockholders worsened to $(49,755,000) for the nine months ended September 30, 2025, compared to $(39,908,000) for the same period in 2024.
• Research and development expenses decreased by $4,429,000 to $26,821,000 in Q3 2025 and by $7,921,000 to $79,966,000 year-to-date, primarily due to completed clinical trials.
• General and administrative expenses decreased by $5,788,000 to $11,935,000 in Q3 2025 and by $3,880,000 to $40,338,000 year-to-date, largely due to lower impairment charges.
• Cash and cash equivalents stood at $95,323,000 as of September 30, 2025, down from $99,120,000 at December 31, 2024.
• Marketable securities decreased to $176,402,000 as of September 30, 2025, from $259,172,000 at December 31, 2024.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $(87,604,000), an improvement from $(102,180,000) in the prior year.
• The company completed its domestication from the Cayman Islands to Delaware effective July 1, 2025, and streamlined its operating subsidiaries for tax purposes.
• Positive Phase 2 REGEN-007 trial results showed a statistically significant 78% improvement in eGFR slope in Group 1 patients, with no rilparencel-related serious adverse events.
• The FDA confirmed that eGFR slope from the ongoing Phase 3 PROACT 1 study can serve as the surrogate endpoint for accelerated approval, with topline data expected in Q2 2027.

Sentiment

Score: 7

Explanation: Strong clinical trial results for rilparencel in Phase 2 and clear FDA guidance for accelerated approval in Phase 3 are significant positive developments for a clinical-stage biotechnology company. These milestones de-risk the development pathway and enhance the potential for future commercialization. However, the company continues to incur substantial losses and relies heavily on capital raises, as evidenced by the new $200 million ATM facility and declining cash and marketable securities. The increased year-to-date net loss for Class A common stockholders indicates ongoing financial challenges despite operational efficiencies.

Positives

• Phase 2 REGEN-007 trial demonstrated a statistically significant and clinically meaningful 78% improvement in annual eGFR slope in Group 1 patients (4.6 mL/min/1.73m2 per year difference, p<0.001).
• A subgroup of Group 1 patients meeting Phase 3 PROACT 1 inclusion criteria showed an even greater 85% improvement in eGFR slope (5.5 mL/min/1.73m2 per year).
• No rilparencel-related serious adverse events were observed in the REGEN-007 study, maintaining a consistent safety profile comparable to a kidney biopsy.
• The FDA confirmed eGFR slope as an acceptable surrogate endpoint for accelerated approval of rilparencel in the Phase 3 PROACT 1 study, with an effect size of at least 1.5 mL/min/1.73m2/year improvement deemed acceptable.
• More than half of the patients required for the accelerated approval analysis in PROACT 1 have been enrolled.
• Operating loss improved to $(38,539,000) in Q3 2025 from $(48,973,000) in Q3 2024.
• Net cash used in operating activities decreased to $(87,604,000) for the nine months ended September 30, 2025, from $(102,180,000) in the prior year.
• The company generated $217,000 in revenue in Q3 2025 and $668,000 year-to-date from leasing activities, establishing a new revenue stream.

Negatives

• Net loss available to Class A common stockholders worsened to $(49,755,000) for the nine months ended September 30, 2025, compared to $(39,908,000) for the same period in 2024.
• Cash and cash equivalents decreased to $95,323,000 as of September 30, 2025, from $99,120,000 at December 31, 2024.
• Marketable securities significantly decreased to $176,402,000 as of September 30, 2025, from $259,172,000 at December 31, 2024.
• Interest income decreased by $2,322,000 in Q3 2025 and $4,082,000 year-to-date, driven by lower investment balances and interest rates.
• The exploratory dosing regimen in REGEN-007 Group 2 showed a 50% improvement in eGFR slope (1.7 mL/min/1.73m2 per year) but was not statistically significant (p=0.085).
• The company expects to need substantial additional funding to support continuing operations and growth strategy, which may lead to further stockholder dilution.

Risks

• Uncertainty regarding the timing and progress of nonclinical and clinical development activities for rilparencel and future product candidates.
• Inability to maintain current research and development programs or establish new ones.
• Challenges in establishing an appropriate safety profile for product candidates.
• Uncertainty in the number of sites and patients involved in clinical trials, and patient enrollment/discontinuation rates.
• Risk of not successfully completing clinical trials with satisfactory safety, tolerability, and efficacy profiles for regulatory authorities.
• Uncertainty in the number of trials required for regulatory approval.
• Risks related to the timing, receipt, and terms of any regulatory approvals.
• Inability to establish new licensing or collaboration arrangements.
• Performance risks associated with future collaborators.
• Challenges in establishing commercial manufacturing capabilities or arrangements with third-party manufacturers.
• Significant and changing government regulation and regulatory guidance.
• Impact of business interruptions on operations or third-party partners.
• Difficulties in obtaining, maintaining, defending, and enforcing patent claims or other intellectual property rights.
• Uncertainty regarding the potential benefits of rilparencel over other therapies.
• Challenges in launching commercial sales of rilparencel, if approved.
• Risk of not maintaining a continued acceptable safety profile of rilparencel following approval.
• Potential for significant additional financial resources and time if regulatory authorities require more clinical trials or if delays occur.
• Risk of never obtaining regulatory approval for any product candidates.
• Risk of product candidates, if approved, not achieving commercial success.
• Dilution of ownership interest for stockholders if additional capital is raised through equity or convertible debt.
• Debt financing and equity financing may involve restrictive covenants.
• Adverse impact on ability to raise additional funds due to worsening global economic conditions and market volatility.
• Inability to obtain additional funding could force delays, reductions, or elimination of R&D programs, product portfolio expansion, or commercialization efforts.

Future Outlook

The company anticipates topline data readout for the eGFR slope, serving as the surrogate endpoint for accelerated approval of rilparencel in the Phase 3 PROACT 1 study, in the second quarter of 2027. Updated guidance on the expected timing of the confirmatory readout for full approval will be provided in the first half of 2026. The company expects its existing cash, cash equivalents, and marketable securities to fund operating expenses and capital expenditure requirements into mid-2027, but will require substantial additional funding thereafter to support ongoing operations, clinical development, potential commercialization, and growth strategies.

Management Comments

• "We anticipate topline data readout of eGFR slope as the surrogate endpoint to support an application for accelerated approval in the second quarter of 2027."
• "We have enrolled more than half of the patients required for the accelerated approval analysis."
• "The FDA agreed that a rilparencel effect size (versus sham controls) of at least 1.5 mL/min/1.73m2/year improvement would be an acceptable demonstration of efficacy in the setting of patients receiving appropriate standard of care therapies."
• "The FDA also confirmed that the ongoing Phase 3 PROACT 1 study may serve as the confirmatory study to support full approval of rilparencel based on the primary time-to-event composite endpoint specified in the protocol."
• "We expect that our existing cash, cash equivalents and marketable securities held at September 30, 2025, will enable us to fund our operating expenses and capital expenditure requirements into mid-2027."
• "We will need substantial additional funding to support our continuing operations and pursue our growth strategy."

Industry Context

ProKidney operates in the highly competitive and capital-intensive biotechnology sector, specifically targeting chronic kidney disease (CKD) with a novel cell therapy, rilparencel. The RMAT designation from the FDA and the agreement on eGFR slope as a surrogate endpoint for accelerated approval position rilparencel favorably within the regulatory landscape, potentially expediting market entry compared to traditional drug development pathways. The positive Phase 2 results for REGEN-007, particularly the statistically significant improvement in eGFR slope, suggest a promising therapeutic approach in a disease area with significant unmet medical need. However, as a clinical-stage company with no product revenue, ProKidney faces typical biotech challenges of high R&D costs, reliance on external funding, and the inherent risks of clinical trial success and regulatory approval. The focus on preserving kidney function rather than managing kidney failure represents a potentially disruptive innovation in CKD treatment.

Comparison to Industry Standards

• The FDA's agreement on an eGFR slope improvement of at least 1.5 mL/min/1.73m2/year as an acceptable demonstration of efficacy for accelerated approval sets a specific benchmark for rilparencel's Phase 3 PROACT 1 study.
• The 78% improvement in annual eGFR slope (4.6 mL/min/1.73m2 per year difference) observed in Group 1 of the REGEN-007 Phase 2 trial is a strong clinical signal, especially when compared to typical rates of eGFR decline in advanced CKD patients, which can range from 3-5 mL/min/1.73m2 per year or more. This suggests a significant potential benefit over standard of care.
• The safety profile of rilparencel, with no related serious adverse events in REGEN-007, is comparable to a kidney biopsy, which is generally considered acceptable for an invasive procedure in this patient population.
• The company's cash runway into mid-2027 is typical for a clinical-stage biotech, but the continuous need for capital raises (e.g., the $200 million ATM facility) reflects the industry standard for funding long and expensive development cycles.

Corporate Governance

Related Party Transactions

• Amended and Restated Exchange Agreement, Lock-Up Agreement, and Tax Receivable Agreement with certain Closing ProKidney Unitholders, effective July 1, 2025, on substantially similar terms to original agreements.
• Consulting Services Agreement with Nefro Health, an Irish partnership controlled and majority-owned by Mr. Pablo Legorreta (a director and significant shareholder). Nefro receives $25,000 per quarter for R&D consulting services.
• Paid Nefro Health $25,000 for the three months ended September 30, 2025, and $75,000 for the nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders: Potential for significant dilution from ongoing and future capital raises. Positive clinical data and FDA clarity could increase long-term value, but continued losses and cash burn pose risks.
• Employees: Continued investment in R&D and G&A functions, including hiring additional personnel, suggests stability and growth in employment opportunities. Equity-based compensation remains a significant component.
• Customers (future): Positive clinical trial results for rilparencel offer hope for a new treatment option for patients with advanced CKD and type 2 diabetes, potentially preserving kidney function.
• Creditors: The company's reliance on equity financing and its pre-revenue status suggest higher risk for debt holders, though current liabilities are manageable relative to assets.
• Regulatory Authorities: The company is actively engaging with the FDA, securing RMAT designation and agreement on accelerated approval endpoints, indicating a cooperative and compliant approach to drug development.

Next Steps

• Continue enrollment for the Phase 3 PROACT 1 study.
• Anticipate topline data readout of eGFR slope for PROACT 1 in Q2 2027 to support accelerated approval.
• Provide updated guidance on the expected timing of the confirmatory readout for PROACT 1 full approval in 1H 2026.
• Seek substantial additional funding through equity, debt, grants, or collaborations to support ongoing operations and growth.
• Evaluate disclosure requirements for new accounting standards (ASU 2023-09, ASU 2024-03, ASU 2025-06).

Key Dates

Recommendation

ProKidney has achieved significant clinical and regulatory milestones with positive Phase 2 data for rilparencel and FDA alignment on an accelerated approval pathway for its Phase 3 study. These developments are highly encouraging for the long-term potential of its lead product candidate and could drive future value. However, the company remains in a pre-revenue stage, incurring substantial operating losses, and is actively raising capital through equity offerings, which will continue to dilute existing shareholders. While the cash runway extends into mid-2027, the need for "substantial additional funding" is explicitly stated. Given the promising clinical progress balanced against the ongoing financial burn and dilution risk inherent in a clinical-stage biotech, a "hold" recommendation is appropriate. Investors should monitor the progress of the PROACT 1 trial and future financing activities closely.

Keywords

ProKidney Corp., rilparencel, REACT, chronic kidney disease, CKD, type 2 diabetes, cell therapy, biotechnology, clinical-stage, Phase 3 trial, PROACT 1, REGEN-007, eGFR slope, FDA accelerated approval, RMAT designation, SEC 10-Q, financial results, biopharmaceutical, kidney function preservation